These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36436331)

  • 1. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
    Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
    Dalvi T; Nørgaard M; Fryzek JP; Movva N; Pedersen L; Pham Hansen H; Walker J; Midha A; Shire N; Boothman AM; Rigas J; Mellemgaard A; Rasmussen TR; Hamilton-Dutoit S; Cronin-Fenton D
    PLoS One; 2023; 18(4):e0284037. PubMed ID: 37040387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib.
    Papazyan T; Denis MG; Sagan C; Raimbourg J; Herbreteau G; Pons-Tostivint E
    Target Oncol; 2024 Jul; 19(4):611-621. PubMed ID: 38825654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
    Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
    Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
    Hamakawa Y; Agemi Y; Shiba A; Ikeda T; Higashi Y; Aga M; Miyazaki K; Taniguchi Y; Misumi Y; Nakamura Y; Shimokawa T; Saigusa Y; Kobayashi N; Okamoto H; Kaneko T
    Cancer Med; 2023 Sep; 12(17):17788-17797. PubMed ID: 37548381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Alves Pinto I; de Oliveira Cavagna R; Virginio da Silva AL; Dias JM; Santana IV; Souza LC; Ferreira da Silva FA; Biazotto Fernandes MF; Junqueira Pinto GD; Negreiros IS; Santiago Gonçalves MF; de Paula FE; Berardinelli GN; Casagrande GMS; Oliveira da Silva M; Albino da Silva EC; de Oliveira MA; Jacinto AA; Duval da Silva V; Reis RM; De Marchi P; Leal LF
    Oncologist; 2022 Nov; 27(11):e899-e907. PubMed ID: 36099421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
    Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
    Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
    BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.